Fig. 1

Aberrant expression of TMPRSS4 and correlation with malignant features of TC patients in TCGA. A and B The relative expression level of TMPRSS4 mRNA in cancer from Oncomine and TIMER2.0. C Comparison of TMPRSS4 expression level between TC tissue (n = 505) and normal control (n = 59) from TCGA database by UALCAN. D Comparison of TMPRSS4 expression level in different lymph node metastasis status (Normal: n = 59, N0: n = 230, N1: n = 58) in TC patients from TCGA database by UALCAN. E Comparison of TMPRSS4 expression level in different histological subtype group including classical PTC (n = 358), tall cell PTC (n = 36), follicular PTC (n = 102), and others (n = 9) in TC patients from TCGA database by UALCAN. F Comparison of TMPRSS4 expression level in different tumor stage (Normal: n = 59, Stage1/2/3/4: n = 284/52/112/55) in TC patients collected in TCGA database by UALCAN. *: P < 0.05, **: P < 0.01, and ***: P < 0.001. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical and endocervical cancer; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic ductal adenocarcinoma; PCPG, paraganglioma and pheochromocytoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carsinosarcoma; UVM, uveal melanoma